SCHEMBL14367451

SCHEMBL14367451

Cc1c(CN(C)C(=O)c2cc3nc(-c4ccc(Cl)cc4)cc(C(F)(F)F)n3n2)cnn1C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.56
HSD17B10 Q99714 6/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
HPGD P15428 4/20 0.56
KMT2A Q03164 3/20 0.54
NPSR1 Q6W5P4 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
KDM4E B2RXH2 7/20 0.54
CASP1 P29466 4/20 0.54
CASP7 P55210 2/20 0.54
MEN1 O00255 2/20 0.54
TSHR P16473 2/20 0.54
PKM P14618 1/20 0.54
TP53 P04637 1/20 0.52
THRB P10828 1/20 0.51
MAPT P10636 4/20 0.51
TTR P02766 1/20 0.50
MAPK1 P28482 2/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14367444 0.86 ALDH1A1 (0.71) ALDH1A1HSD17B10SMN1; SMN2HPGDKMT2A
SCHEMBL14367442 0.83 KDM4E (0.62) ALDH1A1HSD17B10SMN1; SMN2HPGDKMT2A
SCHEMBL16614836 0.82 ALDH1A1 (0.60) ALDH1A1HSD17B10SMN1; SMN2HPGDKMT2A
SCHEMBL1718871 0.81 ALDH1A1 (0.54) ALDH1A1HSD17B10SMN1; SMN2HPGDKMT2A
SCHEMBL14367441 0.78 KDM4E (0.76) ALDH1A1HSD17B10SMN1; SMN2HPGDKMT2A
SCHEMBL1720125 0.77 KDM4E (0.80) ALDH1A1HSD17B10SMN1; SMN2HPGDKDM4E
SCHEMBL1718290 0.77 ALDH1A1 (0.76) ALDH1A1HSD17B10SMN1; SMN2HPGDKMT2A
SCHEMBL1718188 0.76 ALDH1A1 (0.78) ALDH1A1HSD17B10SMN1; SMN2HPGDKMT2A
SCHEMBL1718621 0.75 HSD17B10 (0.69) ALDH1A1HSD17B10SMN1; SMN2HPGDKDM4E
SCHEMBL14367447 0.74 ALDH1A1 (0.73) ALDH1A1HSD17B10SMN1; SMN2HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070270408-A1 Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines NOVO NORDISK A/S (DK) 2007-11-22 US disclosed
US-20070270408-A1 Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines NOVO NORDISK A/S (DK) 2007-11-22 US disclosed
EP-1782859-A2 Pharmaceutical use of substituted pyrazolo [1,5- a]pyrimidines NOVO NORDISK A/S (DK) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070270408-A1 Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines HSD3B1, HSD11B1, SRD5A1 ALDH1A1 133/4885HSD17B10 44/4885SMN1; SMN2 4124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.